{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:59:31Z","timestamp":1794650371006,"version":"4.9.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:p>\n                    Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication. We evaluated the effect among 1411 participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm who received spironolactone mainly as a fourth-line antihypertensive agent for uncontrolled blood pressure and who had valid BP measurements before and during spironolactone treatment. Among those who received spironolactone, the mean age was 63 years (SD: \u00b18 years), 77% were men, and 40% had diabetes. Spironolactone was initiated a median of 3.2 years (interquartile range: 2.0 to 4.4 years) after randomization and added to a mean of 2.9 (SD: \u00b10.9) other antihypertensive drugs. The median duration of spironolactone treatment was 1.3 years (interquartile range: 0.6 to 2.6 years). The median dose of spironolactone was 25 mg (interquartile range: 25 to 50 mg) at both the start and end of the observation period. During spironolactone therapy, mean blood pressure fell from 156.9\/85.3 mm Hg (SD: \u00b118.0\/11.5 mm Hg) by 21.9\/9.5 mm Hg (95% CI: 20.8 to 23.0\/9.0 to 10.1 mm Hg;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001); the BP reduction was largely unaffected by age, sex, smoking, and diabetic status. Spironolactone was generally well tolerated; 6% of participants discontinued the drug because of adverse effects. The most frequent adverse events were gynecomastia or breast discomfort and biochemical abnormalities (principally hyperkaliemia), which were recorded as adverse events in 6% and 2% of participants, respectively. In conclusion, spironolactone effectively lowers blood pressure in patients with hypertension uncontrolled by a mean of \u22483 other drugs. Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension.\n                  <\/jats:p>","DOI":"10.1161\/01.hyp.0000259805.18468.8c","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T20:26:23Z","timestamp":1171916783000},"page":"839-845","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":544,"title":["Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension"],"prefix":"10.1161","volume":"49","author":[{"given":"Neil","family":"Chapman","sequence":"first","affiliation":[{"name":"From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Go\u0308teborg, Sweden; and the Nordic School of Public Health (H.W.), Go\u0308teborg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Dobson","sequence":"additional","affiliation":[{"name":"From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Go\u0308teborg, Sweden; and the Nordic School of Public Health (H.W.), Go\u0308teborg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wilson","sequence":"additional","affiliation":[{"name":"From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Go\u0308teborg, Sweden; and the Nordic School of Public Health (H.W.), Go\u0308teborg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjo\u0308rn","family":"Dahlo\u0308f","sequence":"additional","affiliation":[{"name":"From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Go\u0308teborg, Sweden; and the Nordic School of Public Health (H.W.), Go\u0308teborg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[{"name":"From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Go\u0308teborg, Sweden; and the Nordic School of Public Health (H.W.), Go\u0308teborg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wedel","sequence":"additional","affiliation":[{"name":"From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Go\u0308teborg, Sweden; and the Nordic School of Public Health (H.W.), Go\u0308teborg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R.","family":"Poulter","sequence":"additional","affiliation":[{"name":"From the Imperial College (N.C., J.D., S.W., P.S.S., N.R.P.), London, United Kingdom; the Sahlgrenska University Hospital (B.D.), Go\u0308teborg, Sweden; and the Nordic School of Public Health (H.W.), Go\u0308teborg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.26.22.88"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1966.03110240051022"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1967.00290210057001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197012000-00001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91030-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5816.729"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(78)90132-1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00070.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000040261.30455.b6"},{"key":"e_1_3_2_11_2","first-page":"55","volume":"5","year":"2005","unstructured":"Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone\/renin ratio and spironolactone testing. Clin Med. 2005; 5: 55\u201360.","journal-title":"Clin Med"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(03)01032-X"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(01)02342-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/14746514060060020701"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.11.016"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001683"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200106000-00020"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"e_1_3_2_19_2","first-page":"55","volume":"1","year":"1996","unstructured":"O\u2019Brien E, Mee F, Atkins N. Evaluation of three devices for self-measurement of blood pressure: according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit. 1996; 1: 55\u201361.","journal-title":"Blood Press Monit"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281303"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1427"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03307-9"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14739-3"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1994.tb02519.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001013"},{"key":"e_1_3_2_26_2","first-page":"1863","volume":"85","year":"2000","unstructured":"Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000; 85: 1863\u20131867.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1983.tb03684.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(88)90551-6"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67186-3"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1991.tb01903.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.9.2106"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.0000259805.18468.8c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T12:34:39Z","timestamp":1715517279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.0000259805.18468.8c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1161\/01.HYP.0000259805.18468.8c"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.0000259805.18468.8c","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1079766.532679","asserted-by":"object"}]},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"2006-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}